Angelman Syndrome Foundation opener
  • Walk
  • Contact Registry
  • News
  • Blog
DOnate
  • What is Angelman Syndrome
    • Symptoms and Causes
    • Testing and Diagnosis
    • Genetics of AS
    • Photo Gallery
  • For Parents
    • Newly Diagnosed
    • Accomplishments of Individuals
    • Participate in Research Studies
    • Angelman Therapeutics
  • Research
    • ASF Funded Research
    • Call for Proposals
    • Current Research Studies
    • LADDER
    • Research Funding Philosophy
  • Make an Impact
    • ASF Cure Club
    • Ways To Donate
    • Fundraising for ASF
    • ASF Committees
    • Shop & Support ASF
    • Volunteer Opportunities
  • AS Clinics
    • AS Clinic Patient Survey
  • Resources
    • Search by Topic
    • Adult Resources
    • ASF Family Resource Team
    • ASF Family Fund
    • ASF Family Champions
    • Angelman Syndrome A to Z
    • Communication Training Series
    • Behaviors Training Series
    • Educational Webinars
    • IEP Bank
    • International AS Resources
    • Federal Resources
    • Seizures
    • State Resources
  • Events
    • ASF Walk
    • Conferences and Symposia
    • Bank of America Chicago Marathon
    • Quinn’s Hot Cocoa $4 the Cure
  • About
    • Contact ASF
    • Contact Registry
    • History
    • Board of Directors
    • Communication Advisory Committee
    • Scientific Advisory Committee
    • Receive Our Emails
    • Privacy
    • Financial Transparency
Dr. Jason Yi

articles and announcements

Categories: UBE3A Mutations

Dr. Jason Yi
January 15, 2020

Structure-function studies to characterize UBE3A missense variants

A potentially valuable approach to understand UBE3A function is the characterization of non-truncating missense variants that change one or a few amino acids in the protein. There are hundreds of UBE3A variants, and their functional significance is virtually unknown. The […]

Read more
December 21, 2019

Studies to Determine How Angelman Syndrome-associated Missense Mutations Disrupt UBE3A Function

$200,000 (2 years) Angelman syndrome (AS) is typically caused by genomic deletions that encompass the maternal copy of UBE3A.  In some patients with AS, the UBE3A protein is present but with a single amino acid change known as a missense […]

Read more
December 21, 2019

Preclinical Validation of Behavioral, Molecular, and Electrophysiological Effects of Acamprosate in a Mouse Model of Angelman Syndrome

$81,631 The principal objective of these studies is to determine if acamprosate, a drug that is approved by the Food and Drug Administration for the treatment of alcoholism in adults and works to correct imbalances in excitatory and inhibitory signaling […]

Read more

Recent Posts

  • Joint Initiative between ASA and ASF
  • Groundbreaking ASF Funded Research on Gene Therapy in AS Published in Nature
  • Ovid Therapeutics Collaborates with UCONN Health and Stormy Chamberlain, PhD to Develop Gene Therapy for AS
  • CASS and ASF Announce Collaboration to Increase Support for Families 
  • Ben Philpot, PhD Partners with Deerfield and Pinnacle Hill

Browse

  • What is Angelman Syndrome
  • For Parents
  • ASF Funded Research
  • Make an Impact
  • Angelman Syndrome Clinic Network
  • Events
  • About
  • Resources & Education
  • Contact Registry
  • News
Address Angelman Syndrome Foundation
3015 E. New York Street
Suite A2 #285
Aurora, IL 60504
Phone800.432.6435 Emailinfo@angelman.org

Connect

  • facebook
  • twitter
  • linkedin
  • instagram
  • pinterest
  • rss
  • youtube

The Mission

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.

Copyright © 2021 Angelman Syndrome Foundation. ALL Rights Reserved. | Site design: BRAND INSPIRATION, LLC